Loading...
XKRX
128940
Market cap2.58bUSD
Jul 25, Last price  
282,000.00KRW
1D
-2.93%
1Q
17.50%
Jan 2017
-7.69%
IPO
274.13%
Name

Hanmi Pharm Co Ltd

Chart & Performance

D1W1MN
P/E
29.48
P/S
2.39
EPS
9,567.27
Div Yield, %
0.09%
Shrs. gr., 5y
-0.50%
Rev. gr., 5y
6.07%
Revenues
1.50t
+0.31%
337,380,097,000606,192,086,560674,005,086,850730,133,509,600761,279,849,4701,317,534,519,130882,724,835,490916,586,234,6101,015,962,250,1101,113,649,783,9901,075,853,605,0101,203,185,652,8101,331,546,600,1201,490,887,463,7201,495,501,575,560
Net income
121.32b
-17.04%
-12,698,688,0001,291,575,00022,636,854,46043,933,275,56035,509,505,540154,443,350,26023,325,623,23060,434,211,77034,156,165,93052,109,663,31017,289,714,88067,025,376,13082,791,735,410146,231,157,740121,315,102,380
CFO
193.49b
-10.65%
18,944,112,00061,303,899,48063,268,201,68085,991,520,620-32,819,709,300101,712,291,080412,965,176,320-62,905,201,16025,982,256,13012,446,620,380151,534,949,940201,923,207,360162,268,943,060216,537,615,372193,486,724,950
Dividend
Jun 27, 2024250 KRW/sh
Earnings
Jul 28, 2025

Profile

Hanmi Pharm. Co., Ltd. operates as a pharmaceutical company worldwide. It develops treatments for diabetes, obesity, cancer, autoimmune, and rare diseases. The company was founded in 1973 and is based in Seoul, South Korea.
URL
http://www.hanmi.co.kr/
IPO date
Jul 30, 2010
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,495,501,576
0.31%
1,490,887,464
11.97%
1,331,546,600
10.67%
Cost of revenue
1,091,046,501
1,102,108,119
1,000,944,214
Unusual Expense (Income)
NOPBT
404,455,075
388,779,345
330,602,386
NOPBT Margin
27.04%
26.08%
24.83%
Operating Taxes
30,822,913
28,600,596
19,454,334
Tax Rate
7.62%
7.36%
5.88%
NOPAT
373,632,162
360,178,749
311,148,051
Net income
121,315,102
-17.04%
146,231,158
76.63%
82,791,735
23.52%
Dividends
(12,555,418)
(17,995,573)
(5,992,225)
Dividend yield
0.35%
0.40%
0.16%
Proceeds from repurchase of equity
(3,280,081)
(3,070,611)
(3,834,087)
BB yield
0.09%
0.07%
0.10%
Debt
Debt current
404,753,480
483,775,431
489,193,004
Long-term debt
100,921,204
98,479,941
274,030,768
Deferred revenue
2,044,408
1,033,095
8,457,582
Other long-term liabilities
3,352,138
3,569,810
(38,528,556)
Net debt
151,403,573
280,343,639
544,229,394
Cash flow
Cash from operating activities
193,486,725
216,537,615
162,268,943
CAPEX
(39,261,057)
(47,746,546)
(49,593,078)
Cash from investing activities
24,850,923
(183,472,198)
(181,408,084)
Cash from financing activities
(93,766,989)
(126,786,667)
(36,866,795)
FCF
362,490,000
421,697,053
378,974,098
Balance
Cash
193,195,195
254,155,699
236,736,418
Long term investments
161,075,917
47,756,034
(17,742,040)
Excess cash
279,496,032
227,367,360
152,417,048
Stockholders' equity
868,773,718
728,292,487
853,182,883
Invested Capital
1,307,481,147
1,451,346,550
1,519,567,199
ROIC
27.09%
24.25%
20.84%
ROCE
23.21%
23.17%
19.28%
EV
Common stock shares outstanding
12,680
12,691
12,704
Price
280,500.00
-20.43%
352,500.00
20.65%
292,156.82
5.85%
Market cap
3,556,800,027
-20.50%
4,473,697,350
20.54%
3,711,435,490
5.73%
EV
3,864,061,850
4,898,809,243
4,393,025,981
EBITDA
501,786,175
487,233,324
427,444,393
EV/EBITDA
7.70
10.05
10.28
Interest
24,373,773
28,508,409
22,647,122
Interest/NOPBT
6.03%
7.33%
6.85%